Product Description
KRAS Antibody | 27-016 | ProSci
Host: Rabbit
Reactivity: Human, Mouse, Rat, Drosophila
Homology: N/A
Immunogen: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human KRAS.
Research Area: Cell Cycle, Cancer, Signal Transduction, Immunology
Tested Application: E, WB
Application: KRAS antibody can be used for detection of KRAS by ELISA at 1:62500. KRAS antibody can be used for detection of KRAS by western blot at 1 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50, 000 - 100, 000.
Specificiy: N/A
Positive Control 1: Cat. No. XBL-10407 - Fetal Heart Tissue Lysate
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 22 kDa
Validation: N/A
Isoform: N/A
Purification: Antibody is purified by peptide affinity chromatography method.
Clonality: Polyclonal
Clone: N/A
Isotype: N/A
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Concentration: batch dependent
Storage Condition: For short periods of storage (days) store at 4˚C. For longer periods of storage, store KRAS antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles.
Alternate Name: KRAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, KI-RAS, KRAS1, KRAS2, NS3, RASK2, NS, CFC2
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: KRAS is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma.This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.